IXENSOR
iXensor Co., Ltd. (6734.TWO)
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210726005852/en/
iXensor launches the next generation of integrated COVID-19 screening solution, the PixoHealth Pass Admin App and Web Portal . The PixoHealth Pass Admin App is a virtual gatekeeper, which screens and verifies the COVID-19 related health conditions through a scan of QR code displayed by PixoHealth Pass App users. In addition, the PixoHealth Pass Admin Web Portal synchronizes multi-source COVID-19 related health data and rapid test results from PixoHealth Pass App users and PixoTest® POCT Analyzer simultaneously.
With PixoHealth Pass apps and in-app consent, the authorized institution can track app users’ rapid test results, vaccination status and COVID-19 related symptoms directly on the web portal. The utilization of PixoHealth Pass Admin Web Portal, PixoTest POCT Analyzer and PixoHealth Pass App fully digitizes the data management processes with a one-time setup. In addition, PixoHealth Pass Admin App allows organizations to configure health-data based access management rules for keeping SARS-CoV-2 from causing cluster infections.
The cloud-based data management solution helps streamline COVID-19 testing and point-of-entry screening for semi-closed communities, such as schools, corporations, healthcare facilities, and public health organizations. More important, the computer-vision enabled PixoTest POCT Analyzer detects COVID-19 antigens more accurately than most COVID-19 self-tests. In addition, its wireless connectivity enables easy, fast reporting and case management for routine testing and mass screening, making the reopen of social and economic activities safer and more sustainable.
The PixoTest® POCT COVID-19 Antigen Test detects the nucleoproteins of SARS-CoV-2 in the human nasopharynx and anterior nasal cavity. According to recent technical validation, the PixoTest® POCT COVID-19 Antigen Test proved its ability to capture recombinant nucleocapsid proteins of notable variants, including Alpha, Beta, Gamma and Delta. These variants have undergone mutations in spike proteins on the virus’s surface, which are known to cause the reoccurrences of outbreaks internationally. Thus, seven months post the first launch of COVID-19 vaccines, the evolution of coronavirus seems to have stayed ahead of vaccinations.
iXensor Chairmen Dr. Peter Fitzgerald commented, “The COVID-19 rapid antigen test with an integrated data management solution provides the exact security mechanism demanded to protect homes, schools, businesses and communities from being affected by new outbreaks.
About iXensor
iXensor, the pioneer of mobile health, turns smartphones into lab-grade mobile medical diagnostics. In 2017, iXensor introduced the PixoTest® Blood Glucose Monitoring System as the world's first US FDA-approved smartphone camera-based blood test. Based on the PixoTech® platform, iXensor has ventured into at-home self-testing and clinical point-of-care diagnostics across infectious diseases, women's health, and cardiovascular diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005852/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom